Bile salts in control of lipid metabolism

Current Opinion in Lipidology

Volumn 27, Issue 3, 2016, Pages 295-301

  Schonewille, Marleen ^a   De Boer, Jan Freark ^a   Groen, Albert K ^a,b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

bile salts; cholesterol; farnesoid X receptor; metabolism; triglycerides

Indexed keywords

APOLIPOPROTEIN C2; BILE ACID; BILE SALT; CHOLESTEROL; DNA BINDING PROTEIN; FARNESOID X RECEPTOR; HORMONE RECEPTOR BLOCKING AGENT; ISOPROTEIN; OBETICHOLIC ACID; PROTEIN TYROSINE PHOSPHATASE; TAR DNA BINDING PROTEIN; TRANSCRIPTION FACTOR GATA 4; CELL RECEPTOR;

BARIATRIC SURGERY; BILE ACID SYNTHESIS; CHOLESTEROL BLOOD LEVEL; ENERGY EXPENDITURE; ENERGY METABOLISM; FATTY LIVER; HOMEOSTASIS; HUMAN; HYDROPHOBICITY; INSULIN SENSITIVITY; INTESTINE FLORA; LIPID LIVER LEVEL; LIPID METABOLISM; METABOLIC REGULATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CYTOLOGY; INTESTINE; METABOLISM; MICROBIOLOGY;

ANIMALS; BARIATRIC SURGERY; BILE ACIDS AND SALTS; HUMANS; INTESTINES; LIPID METABOLISM; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION;

EID: 84962113339     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000303     Document Type: Review

References (51)

1. Dawson PA, Karpen SJ. Intestinal transport and metabolism of bile acids. J Lipid Res 2015; 56:1085-1099.
2. Groen AK, Bloks VW, Verkade H, Kuipers F. Cross-talk between liver and intestine in control of cholesterol and energy homeostasis. Mol Aspects Med 2014; 37:77-88.
3. Zhou H, Hylemon PB. Bile acids are nutrient signaling hormones. Steroids 2014; 86:62-68.
4. Kuipers F, Bloks VW, Groen AK. Beyond intestinal soap-bile acids in metabolic control. Nat Rev Endocrinol 2014; 10:488-498.
5. Yuan L, Bambha K. Bile acid receptors and nonalcoholic fatty liver disease. World J Hepatol 2015; 7:2811-2818.
6. Li T, Chiang JY. Bile acids as metabolic regulators. Curr Opin Gastroenterol 2015; 31:159-165.
7. Copple BL, Li T. Pharmacology of bile acid receptors: evolution of bile acids from simple detergents to complex signaling molecules. Pharmacol Res 2016; 104:9-21.
8. Markan KR, Potthoff MJ. Metabolic fibroblast growth factors (FGFs): mediators of energy homeostasis. Semin Cell Dev Biol 2015. [Epub ahead of print]
9. Owen BM, Mangelsdorf DJ, Kliewer SA. Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21. Trends Endocrinol Metab 2015; 26:22-29.
10. Wang DQ, Tazuma S, Cohen DE, Carey MC. Feeding natural hydrophilic bile acids inhibits intestinal cholesterol absorption: studies in the gallstonesusceptible mouse. Am J Physiol Gastrointest Liver Physiol 2003; 285:G494-502.
11. Ryan KK, Tremaroli V, Clemmensen C, et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 2014; 509:183-188.
12. Patti ME, Houten SM, Bianco AC, et al. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring) 2009; 17:1671-1677.
13. Myronovych A, Kirby M, Ryan KK, et al. Vertical sleeve gastrectomy reduces hepatic steatosis while increasing serum bile acids in a weight-loss-independent manner. Obesity (Silver Spring) 2014; 22:390-400.
14. Tailleux A, Rouskas K, Pattou F, Staels B. Bariatric surgery, lipoprotein metabolism and cardiovascular risk. Curr Opin Lipidol 2015; 26:317-324.
15. Mazuy C, Helleboid A, Staels B, Lefebvre P. Nuclear bile acid signaling through the farnesoid X receptor. Cell Mol Life Sci 2015; 72:1631-1650.
16. Li T, Chiang JY. Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev 2014; 66:948-983.
17. Sinal CJ, Tohkin M,Miyata M, et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000; 102:731-744.
18. Zhang Y, Kast-Woelbern HR, Edwards PA. Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation. J Biol Chem 2003; 278:104-110.
19. Huber RM, Murphy K, Miao B, et al. Generation of multiple farnesoid-Xreceptor isoforms through the use of alternative promoters. Gene 2002; 290 (1-2):35-43.
20. Correia JC, Massart J, de Boer JF, et al. Bioenergetic cues shift FXR splicing towards FXRa2 to modulate hepatic lipolysis and fatty acid metabolism. Mol Metab 2015; 4:891-902.
21. Boesjes M, Bloks VW, Hageman J, et al. Hepatic farnesoid X-receptor isoforms alpha2 and alpha4 differentially modulate bile salt and lipoprotein metabolism in mice. PLoS One 2014; 9:e115028.
22. de Aguiar Vallim TQ, Tarling EJ, Ahn H, et al. MAFG is a transcriptional repressor of bile acid synthesis and metabolism. Cell Metab 2015; 21:298-310.
23. Li S, Hsu DD, Li B, et al. Cytoplasmic tyrosine phosphatase Shp2 coordinates hepatic regulation of bile acid and FGF15/19 signaling to repress bile acid synthesis. Cell Metab 2014; 20:320-332.
24. Fu T, Kim YC, Byun S, et al. FXR primes the liver for intestinal FGF15 signaling by transient induction of beta-Klotho. Mol Endocrinol 2016; 30:92-103.
25. Kazgan N, Metukuri MR, Purushotham A, et al. Intestine-specific deletion of SIRT1 in mice impairs DCoH2-HNF-1alpha-FXR signaling and alters systemic bile acid homeostasis. Gastroenterology 2014; 146:1006-1016.
26. Greiner T, Backhed F. Effects of the gut microbiota on obesity and glucose homeostasis. Trends Endocrinol Metab 2011; 22:117-123.
27. Porez G, Prawitt J, Gross B, Staels B. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J Lipid Res 2012; 53:1723-1737.
28. Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science 1999; 284:1362-1365.
29. Parks DJ, Blanchard SG, Bledsoe RK, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999; 284:1365-1368.
30. Song P, Rockwell CE, Cui JY, Klaassen CD. Individual bile acids have differential effects on bile acid signaling in mice. Toxicol Appl Pharmacol 2015; 283:57-64.
31. Sayin SI, Wahlstrom A, Felin J, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 2013; 17:225-235.
32. Zhang X, Osaka T, Tsuneda S. Bacterial metabolites directly modulate farnesoid X receptor activity. Nutr Metab (Lond) 2015; 12:48.
33. Out C, Patankar JV, Doktorova M, et al. Gut microbiota inhibit Asbt-dependent intestinal bile acid reabsorption via Gata4. J Hepatol 2015; 63:697-704.
34. McGavigan AK, Garibay D, Henseler ZM, et al. TGR5 contributes to glucoregulatory improvements after vertical sleeve gastrectomy in mice. Gut 2015. [Epub ahead of print]
35. Flynn CR, Albaugh VL, Cai S, et al. Bile diversion to the distal small intestine has comparable metabolic benefits to bariatric surgery. Nat Commun 2015; 6:7715.
36. Osto E, Doytcheva P, Corteville C, et al. Rapid and body weight-independent improvement of endothelial and high-density lipoprotein function after Rouxen-Y gastric bypass: role of glucagon-like peptide-1. Circulation 2015; 131:871-881.
37. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132:2131-2157.
38. Jiang C, Xie C, Lv Y, et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun 2015; 6:10166.
39. Fang S, Suh JM, Reilly SM, et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med 2015; 21:159-165.
40. Modica S, Petruzzelli M, Bellafante E, et al. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology 2012; 142:355-365.
41. Li P, Ruan X, Yang L, et al. A liver-enriched long noncoding RNA, lncLSTR, regulates systemic lipid metabolism in mice. Cell Metab 2015; 21:455-467.
42. Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013; 145:574-582.
43. Adorini L, Pruzanski M, Shapiro D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today 2012; 17 (17-18):988-997.
44. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 2005; 96:1221-1232.
45. Claudel T, Inoue Y, Barbier O, et al. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology 2003; 125:544-555.
46. Brown JM, Hazen SL. The gut microbial endocrine organ: bacterially derived signals driving cardiometabolic diseases. Annu Rev Med 2015; 66:343-359.
47. Schugar RC, Brown JM. Emerging roles of flavin monooxygenase 3 in cholesterol metabolism and atherosclerosis. Curr Opin Lipidol 2015; 26:426-431.
48. Wang Z, Roberts AB, Buffa JA, et al. Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell 2015; 163:1585-1595.
49. Bennett BJ, de Aguiar Vallim TQ, Wang Z, et al. Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab 2013; 17:49-60.
50. Warrier M, Shih DM, Burrows AC, et al. The TMAO-generating enzyme flavin monooxygenase 3 is a central regulator of cholesterol balance. Cell Rep 2015. [Epub ahead of print]
51. Cheng Q, Inaba Y, Lu P, et al. Chronic activation of FXR in transgenic mice caused perinatal toxicity and sensitized mice to cholesterol toxicity. Mol Endocrinol 2015; 29:571-582.